Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation 1 Supported by NIH Grant CA85381. 1

Carmelo Blanquicett, G. Yancey Gillespie, L. Burt Nabors, C. Ryan Miller, Sumen Bharara, Donald J. Buchsbaum, Robert. B. Diasio and Martin R. Johnson
Carmelo Blanquicett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Yancey Gillespie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Burt Nabors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Ryan Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sumen Bharara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald J. Buchsbaum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert. B. Diasio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin R. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Expression of TP and DPD in GBM (T) and normal brain (N) tissue. As shown above, TP expression is higher in GBM (n = 9) as compared with normal brain (n = 11) with a mean difference of 6.2 (SD = 7.2; P = 0.13). There was no significant difference in DPD expression levels in the same tissue samples (mean difference of 0.32; SD = 2.13; P = 0.76). The average TP/DPD ratio demonstrated in GBM (2.69) is ∼16-fold higher than that of normal brain tissue (0.17) and is primarily because of TP overexpression in GBM. This profile should result in selective conversion of Capecitabine in tumor compared with normal brain tissues (16-fold higher TP/DPD ratio in GBM relative to normal brain).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Schematic of mouse xenograft location(s) and irradiation. One of the two flanks containing a U87MG glioma xenograft was irradiated, whereas the contralateral flank (containing the other U87MG xenograft) as well as the body of the mouse (including the mouse liver) was lead shielded.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    TP expression in irradiated and shielded U87MG glioma xenografts in mice. A, as shown above, TP mRNA levels increased ∼70-fold in irradiated tumors relative to nonirradiated tumors in control mice, remaining elevated 20 days after irradiation. B, of particular interest, TP mRNA levels in the shielded tumors (in the same animal) increased ∼60-fold (relative to initial control levels) 10 and 15 days after irradiation before dropping to control levels at 20 days. Error bars have been incorporated into this figure but are so small as to be obscured by the data point.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    TP expression in shielded normal mouse liver. Mouse TP mRNA expression in normal liver was evaluated in shielded and nonirradiated (control) mice. As shown above, there is no significant difference between shielded and nonirradiated mouse liver TP mRNA levels. Error bars have been incorporated into this figure but are so small as to be obscured by the data point.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    A, effect of irradiation on mRNA expression of 12 cytokines. Cytokine expression in irradiated tumors (days 0–4 after irradiation) was determined for 12 cytokines using a TaqMan Cytokine Gene Expression Plate I as described in “Materials and Methods.” As shown above, IFN-γ demonstrated the greatest increase in expression (6.3-fold) followed by IL-10 (3.7-fold) in irradiated xenografts relative to control xenografts at 4 days after irradiation. IL-1α demonstrated a <2-fold increase in expression 24 h after irradiation (1.6-fold), returning to baseline levels 2–4 days after irradiation. TNF-α levels (included in the cytokine plate) did not increase above baseline. IL-2, IL-4, IL-5, and IL-8, which are not shown, did not demonstrate any increases in expression after irradiation. IL-1β, IL-12p35, IL-12p40, and IL-15 mRNA levels were beyond the limits of detection in all of the samples (data not shown). B, quantitation of TP in U87MG glioma cells without (−) and with (+) IFN-γ. TP expression (mRNA levels) increased 5-fold in the U87MG glioma cells treated with IFN-γ (+) as compared with untreated cells (−), suggesting a direct effect of IFN-γ on TP transcription.

Tables

  • Figures
  • Table 1

    Primer and probe sequences and optimal concentrations

    TargetSequenceOptimal conc. (nm)
    TP (human)
     FwdGGAGAAGGGTGACCGACTCA100
     ProbeFAM-CGCTGAGATCAATCGGCCCGACTAT-TAMRA200
     RevTGCCCAGACTCGGCAAAG200
    TP (mouse)
     FwdCGGCCAGAGTGCAAAGCT200
     ProbeFAM-CAGCATACAGGATCCCATCAGCAGGAA-TAMRA200
     RevTCCACAGTGGCTGTCACATCTC300
    TNF-α
     FwdGGAGAAGGGTGACCGACTCA300
     ProbeFAM-CGCTGAGATCAATCGGCCCGACTAT-TAMRA250
     RevTGCCCAGACTCGGCAAAG200
    S9
     FwdATCCGCCAGCGCCATA100
     ProbeFAM-AGCAGGTGGTGGTGAACATCCCGTCCTT-TAMRA300
     RevTCAATGTGCTTCTGGGAATCC100
    DPD
     FwdCCAAAGGCAGTAAAGCAGGAA300
     ProbeFAM-TGCGCCTGTCACTCTCCATTGCC-TAMRA25
     RevTCACGACTCCCCGTATCGA100
PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (12)
October 2002
Volume 1, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation 1 Supported by NIH Grant CA85381. 1
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation 1 Supported by NIH Grant CA85381. 1
Carmelo Blanquicett, G. Yancey Gillespie, L. Burt Nabors, C. Ryan Miller, Sumen Bharara, Donald J. Buchsbaum, Robert. B. Diasio and Martin R. Johnson
Mol Cancer Ther October 1 2002 (1) (12) 1139-1145;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation 1 Supported by NIH Grant CA85381. 1
Carmelo Blanquicett, G. Yancey Gillespie, L. Burt Nabors, C. Ryan Miller, Sumen Bharara, Donald J. Buchsbaum, Robert. B. Diasio and Martin R. Johnson
Mol Cancer Ther October 1 2002 (1) (12) 1139-1145;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement